Royalty Pharma PLC - CL

Forecast & Rating9 analysts currently cover Royalty Pharma PLC - CL, with about 77.8% giving a positive rating — meaning they expect the stock to rise. The average price target is $59.89, about 0.1% downside from the current price of $59.97. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 11.8% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Royalty Pharma PLC - CL closely still see room for the stock to rise. Data as of Jul 22, 2026; for reference only and not investment advice.